The Food and Drug Administration (FDA) approved moxetumomab pasudotox (Lumoxiti), a bacterial toxin–based drug, for the...

NCI TTC's new start-up license program makes it easier and more financially attractive for start-ups to license a...

The 2018 Technology Showcase featured technologies from the National Cancer Institute and the Frederick National Laboratory for...

The Federal Laboratory Consortium (FLC) for Technology Transfer has recognized three National Cancer Institute ...